Health Care • Biotechnology: Pharmaceutical Preparations
$82.70 ▲ +0.39
(+0.47%)
MKT CAP: $4.63B • VOL: 849.1K
52W L $32 52W H $118
DNTH // SEC EDGAR XBRL STANDARDIZED FINANCIAL STATEMENTS (FA <GO>)
| LINE ITEM (USD / %) | FY 2025
FILED 2025-12-31 | FY 2024
FILED 2024-12-31 | FY 2023
FILED 2023-12-31 |
|---|---|---|---|
| Revenue (Total Sales) | $2.0M | $6.2M | $2.8M |
| YoY Revenue Growth % | -67.3% | +120.6% | — |
| Gross Profit | $895.8K | $2.7M | $1.2M |
| Gross Margin % | 44.0% | 44.0% | 44.0% |
| Research & Development (R&D) | — | — | — |
| Operating Income (EBIT) | -$177.9M | -$101.9M | -$48.2M |
| Operating Margin % | -8739.3% | -1633.7% | -1704.7% |
| Net Income (GAAP) | -$162.3M | -$85.0M | -$43.5M |
| EBITDA (Normalized) | -$177.9M | -$101.6M | -$48.1M |
| Diluted EPS ($/sh) | — | — | — |
| Operating Cash Flow (OCF) | -$129.1M | -$78.2M | -$36.9M |
| Capital Expenditures (CapEx) | $91.6K | $280.6K | $127.2K |
| Free Cash Flow (FCF) | -$129.2M | -$78.5M | -$37.0M |
| FCF Margin % | -6343.4% | -1258.4% | -1308.9% |
| Return on Invested Capital (ROIC %) | -30.6% | -23.7% | -2.5% |
| Cash & Short-Term Equivalents | $51.1M | $22.8M | $279.9M |
| Total Debt (Short + Long Term) | $16.9M | $9.7M | $595.3M |
| Total Stockholders' Equity | $493.4M | $352.5M | $1.22B |
NO QUARTERLY 10-Q XBRL STATEMENTS AVAILABLE IN CURRENT CACHE FOR DNTH.